GlassScriptPhysician profile
Ching H Shih
NPI 1750330999
$7,734.04
in general payments reported to CMS, 2019-2025
20 companies · $347 in 2025
The $347 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,026 · 2020: $898 · 2021: $1,115 · 2022: $1,245 · 2023: $1,438 · 2024: $1,665 · 2025: $347.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,422 · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,422.29 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $1,422.44 | 2019-2025 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $859.14 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $833.67 | 2021-2024 | Vraylar |
| Almatica Pharma LLC | $596.63 | 2021-2025 | Loreev Xr, Sertraline Hcl |
| Teva Pharmaceuticals USA, INC. | $557.62 | 2019-2024 | Uzedy, Austedo Xr, Austedo |
| Lundbeck LLC | $520.24 | 2019-2024 | Rexulti, Abilify Maintena |
| Vanda Pharmaceuticals INC. | $478.01 | 2020-2024 | Hetlioz, Fanapt |
| Janssen Pharmaceuticals, INC | $448.40 | 2021-2024 | Invega Sustenna, Invega Trinza |
| Allergan, INC. | $389.26 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $360.47 | 2020-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $356.51 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $320.53 | 2019-2024 | Trintellix |
| Neurocrine Biosciences, INC. | $215.93 | 2021-2024 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $201.41 | 2024-2025 | Cobenfy |
| Merck Sharp & Dohme LLC | $72.33 | 2022-2023 | Belsomra |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $32.36 | 2019 | |
| Axsome Therapeutics, INC. | $29.44 | 2024 | Auvelity |
| Ironshore Pharmaceuticals INC. | $19.84 | 2019 | |
| Adlon Therapeutics L.P. | $11.58 | 2021 | |
| Neuronetics, INC. | $8.23 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ching Shih listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.